In the past decades, several clinical trials have been conducted to evaluate the efficacy of other targeting HER2 agents including pertuzumab,4 trastuzumab emtansine,5 and lapatinib6, 7 in HER2‐positive GC patients, but none of them resulted in a significant survival benefit. Here, ERBB2 is linked to gastric cancer.